KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Operating Expenses (2016 - 2025)

Acadia Pharmaceuticals has reported Operating Expenses over the past 16 years, most recently at $266.6 million for Q4 2025.

  • Quarterly results put Operating Expenses at $266.6 million for Q4 2025, up 151.27% from a year ago — trailing twelve months through Dec 2025 was $966.7 million (up 32.97% YoY), and the annual figure for FY2025 was $966.7 million, up 32.97%.
  • Operating Expenses for Q4 2025 was $266.6 million at Acadia Pharmaceuticals, up from $242.9 million in the prior quarter.
  • Over the last five years, Operating Expenses for ACAD hit a ceiling of $269.5 million in Q3 2023 and a floor of $106.1 million in Q4 2024.
  • Median Operating Expenses over the past 5 years was $186.6 million (2022), compared with a mean of $194.4 million.
  • Biggest five-year swings in Operating Expenses: plummeted 45.89% in 2024 and later soared 151.27% in 2025.
  • Acadia Pharmaceuticals' Operating Expenses stood at $175.4 million in 2021, then grew by 4.07% to $182.6 million in 2022, then increased by 7.42% to $196.1 million in 2023, then plummeted by 45.89% to $106.1 million in 2024, then soared by 151.27% to $266.6 million in 2025.
  • The last three reported values for Operating Expenses were $266.6 million (Q4 2025), $242.9 million (Q3 2025), and $232.2 million (Q2 2025) per Business Quant data.